PSMA-1007
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 463146

CAS#: 2093321-19-6

Description: PSMA-1007 is a novel Glu-Ureido-type prostate-specific membrane antigen (PSMA) inhibitor. [18F]PSMA-1007 is a prostate specific membrane antigen (PSMA) ligand for positron emission tomography (PET) imaging of prostate cancer.


Chemical Structure

img
PSMA-1007
CAS# 2093321-19-6

Theoretical Analysis

MedKoo Cat#: 463146
Name: PSMA-1007
CAS#: 2093321-19-6
Chemical Formula: C49H55FN8O16
Exact Mass: 1,030.37
Molecular Weight: 1,031.017
Elemental Analysis: C, 57.08; H, 5.38; F, 1.84; N, 10.87; O, 24.83

Price and Availability

Size Price Availability Quantity
1mg USD 350 2 Weeks
5mg USD 1250 2 Weeks
10mg USD 2250 2 Weeks
25mg USD 4650 2 Weeks
50mg USD 6950 2 Weeks
Bulk inquiry

Synonym: PSMA-1007; PSMA1007; PSMA 1007;

IUPAC/Chemical Name: (((S)-1-carboxy-5-((S)-2-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)butanamido)methyl)benzamido)-3-(naphthalen-2-yl)propanamido)pentyl)carbamoyl)-L-glutamic acid

InChi Key: RFFFFGRYVZESLB-LTLCPEALSA-N

InChi Code: InChI=1S/C49H55FN8O16/c50-38-18-14-32(26-52-38)43(66)54-34(16-20-40(61)62)46(69)55-33(15-19-39(59)60)44(67)53-25-27-8-12-30(13-9-27)42(65)56-37(24-28-10-11-29-5-1-2-6-31(29)23-28)45(68)51-22-4-3-7-35(47(70)71)57-49(74)58-36(48(72)73)17-21-41(63)64/h1-2,5-6,8-14,18,23,26,33-37H,3-4,7,15-17,19-22,24-25H2,(H,51,68)(H,53,67)(H,54,66)(H,55,69)(H,56,65)(H,59,60)(H,61,62)(H,63,64)(H,70,71)(H,72,73)(H2,57,58,74)/t33-,34-,35-,36-,37-/m0/s1

SMILES Code: O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC(C1=CC=C(CNC([C@@H](NC([C@@H](NC(C2=CN=C(F)C=C2)=O)CCC(O)=O)=O)CCC(O)=O)=O)C=C1)=O)CC3=CC=C4C=CC=CC4=C3)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,031.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhao H, Li Y, Hou S, Dai Y, Lin C, Xu S. Incidental detection of primary hepatocellular carcinoma on 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography imaging in a patient with prostate cancer: A case report. Medicine (Baltimore). 2020 Oct 9;99(41):e22486. doi: 10.1097/MD.0000000000022486. PMID: 33031282.

2: Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, Vogel WV, Nagarajah J, Janssen M, Isebaert S, Maes F, Mai C, Oyen R, Joniau S, Kunze-Busch M, Goffin K, Haustermans K. Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Oct 6. doi: 10.1007/s00259-020-05059-4. Epub ahead of print. PMID: 33025093.

3: Privé BM, Israël B, Schilham MGM, Muselaers CHJ, Zámecnik P, Mulders PFA, Witjes JA, Sedelaar M, Mehra N, Verzijlbergen F, Janssen MJR, Gotthardt M, Barentsz JO, van Oort IM, Nagarajah J. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2020 Sep 30. doi: 10.1038/s41391-020-00292-2. Epub ahead of print. PMID: 32999466.

4: Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello F. Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2020 Sep 16:101097JU0000000000001369. doi: 10.1097/JU.0000000000001369. Epub ahead of print. PMID: 32935652.

5: Cardinale J, Roscher M, Schäfer M, Geerlings M, Benešová M, Bauder-Wüst U, Remde Y, Eder M, Nováková Z, Motlová L, Barinka C, Giesel FL, Kopka K. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido- Type PSMA Inhibitors. J Med Chem. 2020 Oct 8;63(19):10897-10907. doi: 10.1021/acs.jmedchem.9b01479. Epub 2020 Sep 22. PMID: 32852205.

6: Sprute K, Kramer V, Koerber S, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber W, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. Diagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med. 2020 Aug 17:jnumed.120.246363. doi: 10.2967/jnumed.120.246363. Epub ahead of print. PMID: 32817141.

7: Foley RW, Redman SL, Graham RN, Loughborough WW, Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol. 2020 Aug 8:S0009-9260(20)30273-7. doi: 10.1016/j.crad.2020.06.031. Epub ahead of print. PMID: 32782128.

8: Naka S, Watabe T, Kurimoto K, Uemura M, Soeda F, Neels OC, Kopka K, Tatsumi M, Kato H, Nonomura N, Shimosegawa E, Cardinale J, Giesel FL, Hatazawa J. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):18. doi: 10.1186/s41181-020-00101-0. PMID: 32728815; PMCID: PMC7391460.

9: Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta- Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2020 Jul 13:S2588-9311(20)30090-0. doi: 10.1016/j.euo.2020.06.012. Epub ahead of print. PMID: 32675047.

10: Arçay A, Eiber M, Langbein T. Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET. Clin Nucl Med. 2020 Jul;45(7):561-562. doi: 10.1097/RLU.0000000000003081. PMID: 32433166.

11: Trägårdh E, Minarik D, Brolin G, Bitzén U, Olsson B, Oddstig J. Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer. EJNMMI Phys. 2020 May 12;7(1):31. doi: 10.1186/s40658-020-00298-8. PMID: 32399664; PMCID: PMC7218038.

12: Marafi F, Sasikumar A, Alfeeli M, Thuruthel S. 18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer. Clin Nucl Med. 2020 Jun;45(6):e276-e278. doi: 10.1097/RLU.0000000000003013. PMID: 32332302.

13: Ioppolo JA, Nezich RA, Richardson KL, Morandeau L, Leedman PJ, Price RI. Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga- PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Appl Radiat Isot. 2020 Jul;161:109164. doi: 10.1016/j.apradiso.2020.109164. Epub 2020 Apr 2. PMID: 32321698.

14: Haemels M, Jentjens S, Cleeren F, Sciot R, Lambert J, Van Laere K, Goffin K. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma. Hell J Nucl Med. 2020 Jan-Apr;23(1):79-80. doi: 10.1967/s002449912007. Epub 2020 Mar 31. PMID: 32222733.

15: Marafi F, Sasikumar A, Al-Terki A, Alfeeli M. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma. Clin Nucl Med. 2020 May;45(5):377-378. doi: 10.1097/RLU.0000000000003002. PMID: 32209880.

16: Mittlmeier LM, Unterrainer M, Todica A, Clevert DA, Cyran CC, Schmoeckel E, Rodler S, Bartenstein P, Stief CG, Ilhan H, Staehler M. Advanced Molecular Imaging in Histologically Verified Metanephric Adenoma. Urology. 2020 Jun;140:e10-e11. doi: 10.1016/j.urology.2020.02.025. Epub 2020 Apr 5. PMID: 32171695.

17: Kairemo K, Kangasmäki A, Joensuu T, Seregard S. Eye Symptoms in a Patient With Prostate Cancer. Clin Nucl Med. 2020 May;45(5):370-371. doi: 10.1097/RLU.0000000000002982. PMID: 32149800.

18: Witkowska-Patena E, Budzyńska A, Giżewska A, Dziuk M, Walęcka-Mazur A. Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT. Ann Nucl Med. 2020 Mar;34(3):192-199. doi: 10.1007/s12149-019-01433-x. Epub 2020 Jan 4. PMID: 31902120; PMCID: PMC7033087.

19: Hartrampf PE, Seitz AK, Krebs M, Buck AK, Lapa C. False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):2044-2046. doi: 10.1007/s00259-019-04645-5. Epub 2019 Dec 27. PMID: 31879815.

20: Tang K, Wang Z, Lin J, Zheng X. Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT. Clin Nucl Med. 2020 Mar;45(3):223-224. doi: 10.1097/RLU.0000000000002873. PMID: 31876816.